Oncolytics Biotech R&D spend
Oncolytics Biotech Inc. · ONC (TSX) · Calgary, AB · Pharmaceuticals
Latest R&D (CAD)
$18.6M
Period ended 2025-12-31
Revenue (CAD)
—
— of revenue
R&D by fiscal period
2025
$18.6M
2024
$21.2M
2023
$17.7M
2022
$15.4M
2021
$12.9M
2020
$12.9M
2019
$10.8M
2018
$10.0M
| Period end | R&D (CAD) | Revenue (CAD) | Native R&D | Form | Source |
|---|---|---|---|---|---|
| 2025-12-31 | $18,610,309 | — | $13,314,000 USD | 10-K | SEC EDGAR |
| 2024-12-31 | $21,153,821 | — | $15,443,000 USD | 10-K | SEC EDGAR |
| 2023-12-31 | $17,709,000 | — | $17,709,000 CAD | 20-F | SEC EDGAR |
| 2022-12-31 | $15,432,000 | — | $15,432,000 CAD | 20-F | SEC EDGAR |
| 2021-12-31 | $12,920,000 | — | $12,920,000 CAD | 20-F | SEC EDGAR |
| 2020-12-31 | $12,945,000 | — | $12,945,000 CAD | 20-F | SEC EDGAR |
| 2019-12-31 | $10,817,997 | — | $10,817,997 CAD | 20-F | SEC EDGAR |
| 2018-12-31 | $10,027,994 | $547,707 | $10,027,994 CAD | 20-F | SEC EDGAR |